6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities

Record Retention, Archiving Requirements & Post-Trial Responsibilities

Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is ICH E6(R3) Annex 1 sections 2.12.12 and 3.16.3 and Appendix C — which set no fixed number of years and defer to applicable regulatory requirements and sponsor notification.

Quick Reference: Record retention in clinical research is governed by strict regulatory timelines that are tied to global marketing approval milestones rather than the date a site finishes its last patient visit. Under FDA 21 CFR 312.62(c), investigators must retain records for 2 years following the date a marketing application (NDA/BLA) is approved for the indication being investigated, or, if no application is to be filed or approved, 2 years after the investigation is discontinued and FDA is notified. Under ICH E6(R3) Annex 1 section 2.12.12, essential documents must be retained for at least 2 years post-marketing approval or 2 years post formal discontinuation. Sites must never destroy records without explicit written authorization from the sponsor.

Understanding record retention and post-trial responsibilities is a heavily tested domain on the ACRP-CP examination. Candidates must navigate conflicting regulatory, contractual, and institutional timelines, uphold electronic archiving integrity, and fulfill post-trial ethical duties to human participants.

---

1. Regulatory Framework for Record Retention Timelines

A frequent compliance trap for clinical sites is confusing the completion of site-level activities with the trigger for record retention countdowns. Because an investigational drug development program may continue across hundreds of sites for years after a single site closes, the site cannot independently calculate when records may be destroyed.

┌───────────────────────────────────────────────────────────────────────────┐
│               RECORD RETENTION TIMELINE HIERARCHY RULE                    │
├───────────────────────────────────────────────────────────────────────────┤
│  WHEN REGULATORY, CONTRACTUAL, AND INSTITUTIONAL TIMELINES DIFFER:        │
│                                                                           │
│       FDA Minimum (2 yrs post-NDA)                                        │
│             ▲                                                             │
│       ICH GCP Requirement (2 yrs post-global approval)                    │
│             ▲                                                             │
│       Clinical Trial Agreement (e.g., 10 yrs per contract)                │
│             ▲                                                             │
│       State/Institutional Law (e.g., Age of majority + 7 yrs in peds)    │
│                                                                           │
│  ★ MANDATE: The site MUST comply with the LONGEST, MOST STRINGENT rule!   │
└───────────────────────────────────────────────────────────────────────────┘

---

2. What Must Be Retained: The Complete Essential Trial Archive

Under ICH E6(R3) Appendix C (Essential Documents for the Conduct of a Clinical Trial), the archived site record must be sufficient to reconstruct the entire trial from initiation to closure.

Essential Components of the Site Archive:

1. Investigator Site File (ISF) / Regulatory Binder:
   • All IRB/IEC approved protocol versions, amendments, and blank approved consent forms
   • IRB approval letters, continuing review reports, and IRB membership rosters/compliance letters
   • Form FDA 1572s / Financial Disclosure Forms (FDFs, 21 CFR 54) for all listed investigators
   • Curriculum vitae (CVs), medical licenses, and GCP training certificates for all staff
   • Comprehensive Delegation of Authority Log (DOAL) and Site Training Logs
   • Investigator's Brochure (IB) editions and safety update transmittals
   • All monitoring logs, CRA visit confirmation and follow-up letters, audit certificates
2. Primary Source Documents & Medical Records:
   • Hospital/clinic progress notes, physician notes, nursing notes
   • Diagnostic reports: ECG tracings, imaging scans (DICOM files/CDs), laboratory reports
   • Subject-completed questionnaires, diaries, and electronic Patient-Reported Outcome (ePRO) logs
3. Subject Informed Consent Forms (ICFs):
   • Every original signed and dated paper ICF, assent form, and re-consent document (or validated Part 11 electronic audit trail certificates)
4. Accountability & Chain-of-Custody Records:
   • Master IP accountability logs, temperature logs, shipment receipts, and destruction certificates
   • Biological specimen tracking logs and laboratory shipping manifests

---

3. Physical, Electronic & Off-Site Archiving Standards

Archiving is not merely placing cardboard boxes in a basement. Archived records must remain secure, complete, legible, and rapidly retrievable throughout the entire multi-year retention period.

Physical Archive Requirements:

• Environmental Protection: Fire suppression systems (gas/clean-agent preferred over water sprinklers), climate control (temperature 18-22°C, relative humidity 30-50%), and flood elevation.
• Physical Access Control: Locked storage facilities restricted to authorized archiving personnel via keycard access logs.
• Pest Control: Monitored pest management programs to prevent rodent and insect destruction of paper.

Electronic Record Archiving (21 CFR Part 11 & ALCOA+):

• Certified Copies: Under FDA and ICH guidelines, paper records may be scanned to electronic media if validated scanning processes create a Certified Copy (verified as having all of the same information, attributes, and legibility as the original).
• Audit Trail Preservation: Electronic data systems, eCRFs, and electronic source files must retain all metadata, time stamps, and audit trails.
• Obsolescence Management: Electronic formats must be actively migrated or stored with compatible viewing software to ensure readability decades later as operating systems and file formats evolve.

Off-Site Commercial Storage & Retrieval SLAs:

If a site utilizes a commercial off-site archiving vendor (e.g., Iron Mountain):

• A formal Business Associate Agreement (BAA) and vendor quality agreement must be executed.
• The facility must guarantee a defined Service Level Agreement (SLA) capable of retrieving and delivering physical files to the site within 24 to 48 hours in the event of an unannounced FDA BIMO inspection.

---

4. Record Destruction Protocols & Sponsor Notification Mandates

Under ICH E6(R3) Annex 1 2.12.12, the investigator/institution must take measures to prevent accidental or premature destruction of trial documents.

Non-Negotiable Rules for Record Destruction:

1. Zero Unilateral Destruction: A site, hospital records manager, or PI must never destroy clinical trial records without prior written notification to and express written authorization from the trial sponsor.
2. The Written Sponsor Inquiry Process: When an institutional retention milestone is reached (e.g., 7 years post-study close), the site records coordinator must send a formal registered inquiry to the sponsor asking:
   • Has the New Drug Application (NDA/BLA) been approved globally?
   • Is the IND still active or under regulatory review?
   • Does the sponsor authorize secure destruction of the site trial records, or does the sponsor request continued archiving at the sponsor's expense?
3. PI Departure or Institutional Closure: If the Principal Investigator leaves the institution, retires, or dies, or if the research institution ceases operations:
   • Custody of the records must be formally transferred to a designated successor investigator or institutional archivist.
   • The sponsor must be notified in writing of the new custodian and the exact physical/electronic location of the records.

---

5. Post-Trial Responsibilities to Study Participants

The investigator's and sponsor's ethical and professional responsibilities do not vanish when the final monitoring letter is signed.

┌───────────────────────────────────────────────────────────────────────────┐
│                POST-TRIAL PARTICIPANT RESPONSIBILITIES                    │
├───────────────────────────────────────────────────────────────────────────┤
│  1. CONTINUITY OF CARE                                                    │
│     • Safe transition to standard-of-care medications                     │
│     • Comprehensive discharge summary to primary treating physician       │
├───────────────────────────────────────────────────────────────────────────┤
│  2. POST-TRIAL ACCESS (Declaration of Helsinki Paragraph 34)              │
│     • Open-Label Extension (OLE) protocols                                │
│     • Expanded Access / Compassionate Use for life-saving therapies       │
├───────────────────────────────────────────────────────────────────────────┤
│  3. TRANSPARENCY & RETURNING RESULTS                                      │
│     • Plain-language, lay summaries of trial outcomes                     │
│     • ClinicalTrials.gov aggregate results posting within 12 months       │
└───────────────────────────────────────────────────────────────────────────┘

1. Continuity of Care and Medical Transition

When study treatment concludes, the investigator must ensure participants are safely transitioned back to routine medical care or alternative therapeutic regimens. If stopping an investigational drug abruptly carries withdrawal or rebound risks (e.g., antihypertensives, immunosuppressants, psychiatric medications), a structured titration/tapering schedule must be provided.

2. Post-Trial Access (Declaration of Helsinki Para 34)

The Declaration of Helsinki (Paragraph 34) establishes that in advance of a clinical trial, sponsors and investigators must make provisions for post-trial access for all participants who still need an intervention identified as beneficial in the trial. This is achieved through:

• Open-Label Extension (OLE) Studies: Allowing trial completers to receive the active drug while long-term safety data are collected.
• Expanded Access / Compassionate Use Programs (21 CFR 312 Subpart I): Providing continued access to investigational drugs for patients with serious or life-threatening conditions who have no comparable alternative options.

3. Sharing Aggregate Results with Participants

Modern GCP and bioethical frameworks emphasize transparency. Participants have a moral right to know the scientific outcome of the research to which they contributed.

• Sponsors and sites increasingly provide plain-language summaries (written at an appropriate 6th to 8th-grade reading level) explaining the primary findings and public health impact.
• Under FDAAA 801 and 42 CFR Part 11, sponsors must post aggregate clinical trial results and adverse event summaries to ClinicalTrials.gov within 12 months of the Primary Completion Date.

---

6. Realistic Clinical Scenario & Inspection Pitfalls

Scenario: A large research hospital conducted a Phase III cardiovascular trial that completed its Close-Out Visit in 2021. In 2026 (5 years later), the hospital's warehouse director notes that the storage lease is expiring and seeks to destroy all paper boxes containing the original signed consent forms, source documents, and ISF files, citing the hospital's standard "5-year general document retention policy."

Regulatory Analysis & ACRP-CP Guidance:

1. Severe GCP Violation: Destroying these records violates ICH E6(R3) Annex 1 section 2.12.12, under which records are kept for the period applicable regulatory requirements demand or until the sponsor confirms in writing that they are no longer needed, whichever is longest (US sites are additionally bound by 21 CFR 312.62(c), which is context rather than ACRP-CP exam content). The sponsor's NDA was submitted in 2024 and received FDA approval in late 2025. The mandatory FDA retention clock (2 years post-NDA approval) extends through at least late 2027.
2. Consequences: If destroyed, an FDA BIMO inspection of the sponsor or site would cite the site for permanent loss/destruction of trial source records, invalidating subject data from the pivotal application and potentially triggering Warning Letters or disqualification proceedings.
3. Proper Action: The site coordinator must halt destruction, verify the status with the sponsor in writing, and arrange for continued archiving paid by the sponsor or transferred to an authorized long-term archive.